holding up well, page-38

Wont be long now ... IMO

Roche Holding AG, InterMune Inc and Pharmasset announced that the first patients have been dosed with a combination of two experimental compounds - R7227 and R7128- in an innovative clinical trial in patients chronically infected with the hepatitis C virus. The trial run in centers in Australia and New Zealand, and is the first to investigate the combination of two oral antiviral molecules in the absence of interferon

Roche Holding AG, InterMune Inc and Pharmasset announced that the first patients have been dosed with a combination of two experimental compounds in an innovative clinical trial in patients chronically infected with the hepatitis C virus.

According to the company, the initial study, dubbed INFORM-1, will evaluate the safety and combined antiviral activity of R7227 (ITMN 191), a protease inhibitor, and R7128, a polymerase inhibitor, in 14 days of combination therapy in treatment-naive patients infected with HCV genotype 1, in the absence of interferon.

With Intermune, Roche is developing R7227, to be used in combination with Pegasys and Copegus, the current standard of care. Concurrently with Pharmasset, Roche is developing R7128, also for therapy in combination with Pegasys an Copegus.

The trial run in centers in Australia and New Zealand.

http://en.networkmedica.com